First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

HC Chung, YJ Bang, CS Fuchs, SK Qin, T Satoh… - Future …, 2021 - Future Medicine
HC Chung reports grants to his institution and writing support from MSD during the conduct
of the study. He also reports grants to his institution from Amgen, BeiGene, BMS/Ono, GSK, …

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer …

YJ Bang, E Van Cutsem, A Feyereislova, HC Chung… - The Lancet, 2010 - thelancet.com
Background Trastuzumab, a monoclonal antibody against human epidermal growth factor
receptor 2 (HER2; also known as ERBB2), was investigated in combination with …

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …

…, L Fornaro, T Olesiński, C Caglevic, HC Chung… - The Lancet, 2018 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …

…, R Shapira-Frommer, K Nakagawa, HC Chung… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of high …

[HTML][HTML] Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE …

…, SA Piha-Paul, T Doi, B Gao, HC Chung… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations …

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO …

…, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung… - The Lancet, 2017 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer refractory
to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, …

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

YJ Bang, YW Kim, HK Yang, HC Chung, YK Park… - The Lancet, 2012 - thelancet.com
Background D2 gastrectomy is recommended in US and European guidelines, and is
preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy …

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

…, J Tabernero, L Li, S Shah, P Bhagia, HC Chung - Nature, 2021 - nature.com
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma

DVT Catenacci, M Rosales, HC Chung, HH Yoon… - Future …, 2021 - Future Medicine
HC Chung reports grants and research support from Amgen, BeiGene, Bristol-Myers
Squibb/Ono Pharmaceutical, Celltrion Healthcare, Lilly, GlaxoSmithKline, Incyte, Merck Serono, …

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …

…, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung… - The Lancet …, 2022 - thelancet.com
Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. …